US FDA accepts Pfizer’s sNDA for priority review of Rapamune to treat LAM
The company estimates the FDA decision for the sNDA in June 2015 based on the anticipated Prescription Drug User Fee Act (PDUFA) action date. Pfizer Global Innovative Pharmaceuticals
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.